# Prof. Vandana Patravale's research group wins Best Poster Award at ICMR International Conference

Ms. Rashmi Prabhu from Prof. Vandana Patravale's research group has won the Best Poster Award for their work entitled "Paclitaxel Nanostructured Lipid Carriers for Treatment of Triple Negative Breast Cancer" at International Conference on Women's Reproductive Health: A step towards improving quality of life organized by Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive Health (NIRRH) on February 20-23, 2020, Mumbai. This conference was a part of ICMR-NIRRH Golden Jubilee Celebrations and was inaugurated by Honourable Union Minister for Health and Family Welfare Dr. Harsh Vardhan. The work was carried out in collaboration with Dr. Vikas Dighe, Toxicology Division, ICMR-NIRRH, Mumbai. The present work explores the application of lipid-based paclitaxel nanocarriers for the potential treatment of triple negative breast cancer (TNBC). Anticancer activity of paclitaxel nanocarriers was evaluated in human TNBC cell lines in vitro. In vivo antitumor efficacy study was performed in murine TNBC 4T1 induced Balb/c mice in comparison to Intaxel® by intravenous delivery and treatment-associated toxicity was also assessed. The award was presented by Dr. S.K. Sikdar, Deputy Commissioner of Family Planning, Ministry of Health and Family Welfare.


INDIAN COUNCIL OF MEDICAL RESEARCH
icmr
NIRRH
NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH
50th Anniversary
ICMR-NIRRH
Golden Jubilee Celebrations
International Conference
on
Women's Reproductive Health:
A step towards
improving quality of life
20-23 February 2020, Mumbai, India
50 Years of NIRRH (1970-2020)
Commemorating five decades of advancements
in reproductive and sexual health
Canara Bank
University of Mumbai
SERB
DIA


PACLITAXEL NANOSTRUCTURED LIPID CARRIERS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
BACKGROUND
RATIONALE
OBJECTIVE
Paclitaxel Nanostructured lipid carriers (Pac NLC)
IN VITRO ANTICANCER ACTIVITY
IN VIVO ANTITUMOR EFFICACY
TREATMENT ASSOCIATED TOXICITY